The Federal Trade Commission has agreed to settle its legal action against a private equity portfolio company that the agency alleged was used to acquire multiple anesthesiology practices and increase prices in Texas, according to court filings made public on Thursday.
The enforcement action targeted U.S. Anesthesia Partners, which the FTC sued under the Biden administration. The agency framed the suit as part of a broader effort to confront private equity rollups - transactions in which a firm purchases numerous small operators within an industry and which the agency argues can reduce competition.
The settlement itself is being kept confidential for now. The FTC said that confidentiality is intended to "facilitate the negotiations USAP must undertake." The agency described the outcome it expects from the deal as a restoration of a competitive market structure and said the resolution will align with the agency's longstanding settlement practices. The FTC also warned that if U.S. Anesthesia Partners does not fully execute the terms of the settlement, the agency will resume its litigation.
Court documents say the rollup at issue encompassed more than a dozen anesthesiology practices and involved roughly 1,000 doctors and 750 nurses. Those figures were presented by the FTC as context for its allegations about the scope of the consolidation.
The private equity firm that created U.S. Anesthesia Partners, Welsh, Carson, Anderson & Stowe, was initially a defendant in the case but reached a separate resolution with the FTC after successfully obtaining dismissal of claims against it.
The agency noted that although it has made healthcare a priority under the prior administration, it remains willing to settle when it determines that negotiated terms will adequately address competitive concerns. Private equity firms and other industry participants are anticipated to study the settlement terms closely once they become available.
Context and implications
The FTC's move highlights continued regulatory scrutiny of private equity-led consolidation in healthcare. The confidential nature of the settlement leaves uncertainty about the specific remedies that will be imposed and how quickly competitive conditions in the affected Texas markets will change.